Neurocrine Biosciences (NBIX) EPS (Basic) Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) EPS (Basic) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.17% |
| Mar 31, 2026 | 42.03% |
| Dec 31, 2025 | -16.20% |
| Sep 30, 2025 | 40.19% |
| Jun 30, 2025 | 4.87% |
| Mar 31, 2025 | -27.80% |
| Dec 31, 2024 | 22.57% |
| Sep 30, 2024 | 17.01% |
| Jun 30, 2024 | 2.81% |
| Mar 31, 2024 | 19.01% |
| Dec 31, 2023 | 48.68% |
| Sep 30, 2023 | 8.65% |
| Jun 30, 2023 | 15.04% |
| Mar 31, 2023 | -11.05% |
| Dec 31, 2022 | 51.36% |
| Sep 30, 2022 | 43.09% |
| Jun 30, 2022 | 25.55% |
| Mar 31, 2022 | 16.66% |
| Dec 31, 2021 | 30.33% |
| Sep 30, 2021 | 20.44% |